1/16
Why do we use 100,000 CFU/mL as our cut-off for true bacteriuria?
This question was posed to me by @BryanCiccarelli. The answer has an interesting history so I thought I'd share it here.
2/ Much of the reliance on urine cultures grew out of the observation that many patients found to have pyelonephritis on autopsy were never diagnosed before death.
It seemed that using clinical findings alone wasn’t good enough.
Maybe bacteria identified in voided urine could be used as a surrogate for bladder bacteriuria/infection and/or pyelonephritis.
4/ There is a problem, of course.
False-positive urine cultures (i.e., “contamination”), particularly with these voided urine samples.
It wasn’t enough to have bacteriuria. We needed a value above which contamination became less likely and infection became more likely.
5/ In the 1950s, Edward Kass performed a series of studies with the goal of determining what number of bacteria - in voided urine - provided a clue to the diagnosis of pyelonephritis.
Kass used clinical features as the “gold standard” for diagnosis.
16/16
📌The search for a level of bacteriuria consistent with UTI emerged from a desire to avoid missed pyelonephritis
📌Though >10⁵ CFU/mL has long been associated with true positive bacteriuria, in those who are symptomatic this value has low sensitivity
• • •
Missing some Tweet in this thread? You can try to
force a refresh
You are seeing a patient recently diagnosed with heart failure and started on GDMT. You notice that their hemoglobin (HGB) has increased (12 → 13 g/dL) in the intervening weeks.
🤔Which medication is the likely cause of this increase in HGB?
2/12 - An Answer
Empagliflozin
💡All SGLT2 inhibitors have been associated with an increase in hematocrit/hemoglobin soon after initiation.
The average increase is 2.3% in hematocrit and 0.6 g/dL in hemoglobin.
The effect of SGLT2 inhibitors on HCT/HGB has been noted since the very first randomized control trial of dapagliflozin, published in 2010.
Initially, investigators assumed this was related to the diuretic effect of these drugs (i.e., a reduction in plasma volume led to an increase in HCT/HGB).
3/ The mutation in the Factor V gene conferring resistance to activated protein C was detailed the following year by a group in Leiden, The Netherlands.